登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000415 证券简称：渤海租赁 公告编号：2025-036 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第一季度报告是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 √否 ■ 注： 1、报告期内，公司营业收入较上年同期增加85.51亿元，同比增长99.82%，主要系本期飞机销售和飞机 租赁收入增加所致。 2、报告期内，公司归属于上市公司股东的净利润较上年同期增加2.81亿元，同比增长72.21%，归属于 上市公司股东扣除非经常性损益的净利润较上年同期增加2.29亿元，同比增长106.81%，主要系以下原 因所致： （1）受益于航空客运需求的持续回 ...

Core Viewpoint - The company reported a net profit attributable to shareholders of -128.43 million yuan for 2024, leading to a decision not to distribute profits or increase capital reserves for the year [4][52]. Company Overview - The company operates in the paper and cellulose acetate industries, producing food packaging paper, household paper, and cellulose acetate [5][7]. - In 2024, the company produced 259,800 tons of paper, a decrease of 18.79% year-on-year, and sold 281,200 tons, down 9.7% [7]. - The cellulose acetate production was 28,600 tons, an increase of 0.93%, with sales reaching 27,100 tons, up 1.06% [7]. Financial Performance - The company faced significant challenges in the paper industry due to fluctuating raw material prices, high energy costs, and reduced terminal demand, resulting in a narrowing profit margin [5]. - The total revenue for the paper and paper products industry in China was 1,456.62 billion yuan in 2024, with a year-on-year growth of 3.9% [5]. - The overall profit for the industry was 51.97 billion yuan, reflecting a year-on-year increase of 5.2% [5]. Challenges and Strategic Responses - The company identified several factors contributing to its losses, including a challenging market environment for food packaging paper, procurement cycle impacts, and the need for asset impairment provisions [53]. - To address these challenges, the company implemented organizational reforms, aimed to enhance production efficiency, and planned to expand into high-value areas such as bio-based materials [55]. Governance and Compliance - The company’s board and supervisory committee confirmed the authenticity and completeness of the annual report, ensuring compliance with relevant laws and regulations [3][14]. - The company’s financial statements for the first quarter of 2025 were prepared without audit, reflecting ongoing adjustments due to the acquisition of a subsidiary [80]. Accounting Policy Changes - The company made changes to its accounting policies in accordance with new regulations issued by the Ministry of Finance, which are not expected to have a significant impact on its financial status [70][72]. Shareholder Information - The company reported that its unallocated losses exceeded one-third of its paid-in capital, necessitating a review at the upcoming shareholder meeting [52].

Group 1 - The company has proposed to purchase liability insurance for its directors, supervisors, and senior management to mitigate operational risks and protect their rights [57][58] - The insurance coverage limit is set at no more than 30 million RMB, with an annual premium not exceeding 250,000 RMB [58] - The proposal requires approval from the shareholders' meeting as the directors and supervisors are the insured parties and will abstain from voting [57][58] Group 2 - The company reported a net loss of 307.93 million RMB for the fiscal year 2024, with an unallocated profit of -272.11 million RMB as of December 31, 2024, exceeding one-third of the paid-in capital of 242.37 million RMB [60][61] - The loss is attributed to a significant decline in the market prices of lithium compounds and derivatives, impacting revenue and gross profit [61] - The company has conducted impairment tests on various assets, leading to substantial impairment provisions, which have further affected the financial results [62] Group 3 - The company plans to cancel 1.17 million stock options that have expired and remain unexercised, which accounts for 0.48% of the total share capital [41][49] - This cancellation is in compliance with the relevant regulations and will not have a significant impact on the company's financial status or operational performance [49][50] - The decision has been approved by the board and the supervisory committee, ensuring that it does not harm the interests of shareholders [50] Group 4 - The company has announced a daily related transaction with its affiliate, Jing Shan Hua Xia Industrial Technology Co., Ltd., with an estimated total amount not exceeding 3 million RMB for leasing factory premises in 2025 [30][31] - This transaction has been approved by the board and does not require further shareholder approval as it does not constitute a major asset restructuring [30][31] - The pricing for the transaction is based on market rates, ensuring fairness and compliance with regulations [35][37] Group 5 - The company has undergone a change in accounting policies in accordance with the Ministry of Finance's new interpretations, which will not have a significant impact on its financial statements [51][55] - The changes are aimed at ensuring that the company's financial reporting remains accurate and compliant with the latest regulations [55]

Core Viewpoint - The company, Zhejiang Zhonghe Technology Co., Ltd., has disclosed its first-quarter financial report for 2025, emphasizing the accuracy and completeness of the information provided, including the recognition of asset impairment provisions [1][2][8]. Financial Data - The first-quarter report for 2025 was not audited [7]. - The company has not made any retrospective adjustments or restatements to previous accounting data [3]. - The company has recognized asset impairment provisions for accounts receivable, other receivables, and contract assets, amounting to a total of 1,984.95 million yuan in credit impairment losses, with an additional 190.43 million yuan in asset impairment losses [11]. Shareholder Information - The company completed a private placement of 130,209,496 shares at a price of 5.25 yuan per share in July 2024, with the shares listed on August 1, 2024. The lock-up period for these shares was lifted on February 11, 2025 [5]. Impairment Provisions - The company applied a simplified measurement method for estimating expected credit losses on receivables and contract assets, considering historical credit loss experience and current conditions [8][9]. - Specific provisions were made for various categories, including bad debt provisions for notes receivable, accounts receivable, and contract assets [11].

Core Viewpoint - The company has announced the provision for asset impairment, reflecting a cautious approach in accordance with accounting standards and regulations [8][11][24]. Financial Data - The first quarter report for 2025 has not been audited [3][7]. - The company has reported a total provision for bad debts of 6,890,455.28 yuan, with a reversal of 2,020,373.58 yuan [9]. - The provision for inventory impairment amounts to 133,476.69 yuan, with a write-off of 2,048.70 yuan [10]. Shareholder Information - The company has confirmed that there are no changes in the top ten shareholders due to the lending or returning of shares [5]. Board and Supervisory Committee Decisions - The board and supervisory committee have both approved the asset impairment provision, confirming its compliance with accounting standards and reflecting the company's financial status accurately [12][24]. - The board meeting held on April 29, 2025, had full attendance and passed the resolution with unanimous support [16][20].

Core Viewpoint - The company has disclosed its financial performance and significant events, including the issuance of new shares and the provision for asset impairment, reflecting its ongoing financial management and strategic adjustments in response to market conditions [3][6][15]. Financial Data Summary - The company reported a total asset impairment provision of 27,617,741.97 yuan for the first quarter of 2025, which will reduce the net profit attributable to the parent company by 27,588,451.58 yuan after considering tax effects [15][17]. - The company has not restated or adjusted previous years' financial data, indicating stability in its accounting practices [3][4]. Share Issuance and Capital Management - The company received approval from the China Securities Regulatory Commission to issue up to 27,792 million new shares, with the issuance completed on August 4, 2023, increasing the total shares from 926,400,000 to 1,136,373,753 [6][7]. - The company plans to continue using idle raised funds for cash management, with a limit of 400 million yuan for a period not exceeding 12 months [10]. Asset Impairment and Financial Health - The company conducted a comprehensive review of its assets, including inventory and receivables, leading to the decision to provision for asset impairment based on prudence and market conditions [16][18]. - The audit committee has confirmed that the asset impairment provision is in accordance with accounting standards and reflects the company's financial condition accurately [18]. Corporate Governance and Accountability - The board of directors and senior management have guaranteed the accuracy and completeness of the quarterly report, accepting legal responsibility for any misstatements [2][3].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688310 证券简称：迈得医疗 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一) 主要会计数据和财务指标 单位：元 币种：人民币 (二) 非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 对公司将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号——非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 □适用 √不适用 (三) 主要会计数据、财务指标发生变动的情况、原因 √适用 □ ...

Core Viewpoint - The company reported a decline in net profit for the first quarter of 2025, primarily due to changes in the VAT calculation method for in vitro diagnostic reagents, leading to a decrease in operating revenue compared to the same period last year [4][5][6]. Financial Data Summary - The first quarter financial report is unaudited [3]. - The company's net profit decreased compared to the same period last year, attributed to the adjustment of the VAT calculation method for in vitro diagnostic reagents, resulting in a decline in operating revenue [4]. - The net cash flow from operating activities decreased by 134.97% compared to the same period last year, mainly due to reduced accounts receivable collections from the subsidiary [4]. Shareholder Information - As of the end of the reporting period, the company held 1,291,428 shares in its repurchase account, accounting for 3.23% of the total share capital [6]. Board Meeting Resolutions - The company held its 11th meeting of the second board on April 28, 2025, where several resolutions were passed, including the approval of the 2024 annual general manager's work report and the 2024 annual board work report [9][11]. - The board also approved the 2024 financial settlement report and the 2024 annual report, which will be submitted for shareholder approval [13][16]. Profit Distribution Plan - The company proposed a cash dividend of 1.00 yuan per 10 shares (including tax), with a total distribution amounting to 3,870,857.20 yuan based on the adjusted total shares [99][100]. - The profit distribution plan is subject to approval at the 2024 annual general meeting [101][103]. Related Transactions - The company plans to use idle funds to purchase financial products from Jiangnan Rural Commercial Bank, with a maximum balance of 50 million yuan and a term not exceeding 12 months [63][64]. - This transaction has been approved by the board and will be submitted for shareholder approval [79][80]. Audit Firm Appointment - The company intends to reappoint Lixin Certified Public Accountants as its auditor for the 2025 fiscal year, pending shareholder approval [86][87]. - Lixin has a strong track record and has provided audit services to numerous listed companies [88][89].

Core Viewpoint - The company reported a steady recovery in its business operations during the first quarter of 2025, with a year-on-year revenue growth of 0.54% and a quarter-on-quarter growth of 12.37% despite external pressures [3]. Financial Performance - The company achieved operating revenue of 0.92 billion yuan in the first quarter of 2025, reflecting a year-on-year increase of 0.54% and a quarter-on-quarter increase of 12.37% [3]. - The overseas market showed significant growth, with overseas revenue increasing by 69.00% year-on-year due to prior product certifications and strategic deployment [3]. - The net profit declined due to price pressures from centralized procurement in the in vitro diagnostics industry, a VAT adjustment on self-produced testing reagents to 13%, and a reduction in government subsidies [3]. Asset Impairment - The company conducted impairment testing on its assets as of March 31, 2025, and recognized a total impairment provision of 59.06 thousand yuan, which included 18.64 thousand yuan for expected credit losses and 40.42 thousand yuan for inventory write-downs [13][14]. - The impairment provisions are expected to increase the company's profit before tax by 318.29 thousand yuan for the first quarter of 2025 [14]. Governance and Compliance - The board of directors and the supervisory board confirmed the accuracy and completeness of the quarterly report, ensuring compliance with relevant laws and regulations [2][8]. - The supervisory board reviewed and approved the first quarter report, affirming that it reflects the company's financial status and operational results accurately [8][9].

2024年，公司及子公司在不影响公司正常经营资金需求和确保资金安全的前提下，使用部分暂时闲置的 自有资金进行委托理财，总额度不超过10亿元。截至2024年12月31日，未到期理财余额为5.13亿元。 具体内容详见公司同日发布在巨潮资讯网（www.cninfo.com.cn）上的《智度科技股份有限公司关于 2024年度证券投资情况的专项说明》。 （十）《智度科技股份有限公司2025年度董事薪酬方案》 因该事项与全体董事存在利害关系，因此全体董事回避表决，本议案将直接提交公司股东会审议。 具体内容详见公司同日发布在巨潮资讯网（www.cninfo.com.cn）上的《智度科技股份有限公司2025年 度董事、监事及高级管理人员薪酬方案》。 登录新浪财经APP 搜索【信披】查看更多考评等级 （九）《智度科技股份有限公司关于2024年度证券投资情况的专项说明》 表决结果：五票同意、零票反对、零票弃权。本议案获得通过。 表决结果：三票同意、零票反对、零票弃权。本议案获得通过。 关联董事陆宏达先生和刘广飞先生回避表决。 具体内容详见公司同日发布在巨潮资讯网（www.cninfo.com.cn）上的《智度科技股份有限公司关于 ...